Study examining the comparative efficiency of Lucentis and less costly Avastin in the treatment of macular degeneration shows no evidence of one product having better efficiency over the other
Study shows expensive Lucentis treatment for macular degeneration is no more efficiency than cheaper Avastin developed by Roche
XOMA announced it's been awarded a federal R&D contract to research antibodies possibilites in H1N1 fight
On Sept 14, 2009 XOMA announces its plan to fully repay Goldman Sachs $44 million loan. This will be done by the end of 2009 through the use of a previously-secured equity credit line, restricted cash from operations and royalties from sales of lucentus.